- Home
- ATAI vs ITOS Comparison
ATAI vs ITOS Comparison
Compare ATAI & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- ITOS
- Stock Information
- Founded
- ATAI 2018
- ITOS 2011
- Country
- ATAI Germany
- ITOS United States
- Employees
- ATAI N/A
- ITOS N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATAI Health Care
- ITOS Health Care
- Exchange
- ATAI Nasdaq
- ITOS Nasdaq
- Market Cap
- ATAI 282.6M
- ITOS 270.7M
- IPO Year
- ATAI 2021
- ITOS 2020
- Fundamental
- Price
- ATAI $1.41
- ITOS $6.70
- Analyst Decision
- ATAI Strong Buy
- ITOS Strong Buy
- Analyst Count
- ATAI 3
- ITOS 3
- Target Price
- ATAI $10.50
- ITOS $25.67
- AVG Volume (30 Days)
- ATAI 1.4M
- ITOS 553.7K
- Earning Date
- ATAI 05-19-2025
- ITOS 04-28-2025
- Dividend Yield
- ATAI N/A
- ITOS N/A
- EPS Growth
- ATAI N/A
- ITOS N/A
- EPS
- ATAI N/A
- ITOS N/A
- Revenue
- ATAI $308,000.00
- ITOS $35,000,000.00
- Revenue This Year
- ATAI $65.58
- ITOS N/A
- Revenue Next Year
- ATAI N/A
- ITOS $31.74
- P/E Ratio
- ATAI N/A
- ITOS N/A
- Revenue Growth
- ATAI N/A
- ITOS 177.89
- 52 Week Low
- ATAI $1.03
- ITOS $4.80
- 52 Week High
- ATAI $2.57
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- ATAI 44.57
- ITOS 49.45
- Support Level
- ATAI $1.36
- ITOS $6.58
- Resistance Level
- ATAI $1.54
- ITOS $7.80
- Average True Range (ATR)
- ATAI 0.09
- ITOS 0.51
- MACD
- ATAI -0.00
- ITOS -0.03
- Stochastic Oscillator
- ATAI 0.00
- ITOS 32.10
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.